Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX)
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 04/19/16 -- announced today that it has updated coverage on Soligenix, Inc. ("The Company" or "SNGX") (OTCBB: SNGX), a clinical stage biopharmaceutical company based in Princeton, New Jersey, with a twelve-month price target of $4.50. Ross Silver, Principal Analyst at Vista Partners, stated, "Randal J. Kirk, the CEO of Intrexon which has approximately a $4.3B market cap, has a beneficial ownership position of approximately 20% of Soligenix. In addition, Paolo Cavazza''s beneficial ownership position on his own behalf and on behalf of Sigma-Tau is approximately 10% of Soligenix." Mr. Silver concludes, "Soligenix recently reported positive preliminary data from the Phase 2 trial of their clinical candidate SGX942 for the treatment of oral mucositis associated with head & neck cancers. It is estimated that 500,000 patients suffer from oral mucositis, including 40% of patients receiving chemotherapy. On the conference call with investors to discuss the preliminary data of the SGX942 Phase 2 trial, The market cap of Soligenix on April 18, 2016 was approximately $22M, 4x less than the $100M stated value of SGX942 according to management.
To download a FREE copy of the research report, please visit and click the "download research" icon to gain access to the report. The iShares Nasdaq Biotechnology (NASDAQ: IBB), a popular biotech ETF, has gained approximately 6% so far in the month of April.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm''s professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista''s mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.
Please follow us on & at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website or click .
Contact:
Vista Partners
877.215.4813
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.04.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 1429008
Anzahl Zeichen: 4523
contact information:
Contact person:
Town:
SAN FRANCISCO, CA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX)
"
steht unter der journalistisch-redaktionellen Verantwortung von
Vista Partners LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
